A pharmacologic strategy for the treatment of nicotine addiction

Synapse

Volumn 31, Issue 1, 1999, Pages 76-86

  Dewey, Stephen L ^a,b   Brodie, Jonathan D ^b   Gerasimov, Madina ^a   Horan, Bryan ^c   Gardner, Eliot L ^d   Ashby Jr , Charles R ^c  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ST JOHN'S UNIVERSITY   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Conditioned place preference; Gamma vinyl GABA (Vigabatrin); Microdialysis; Nicotine; Positron emission tomography; Substance abuse; Treatment

Indexed keywords

NICOTINE; RACLOPRIDE; VIGABATRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DRUG DEPENDENCE; DRUG EFFECT; GABAERGIC TRANSMISSION; LIGHT DARK CYCLE; MICRODIALYSIS; NONHUMAN; PLACE PREFERENCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; SMOKING CESSATION; SUBSTANCE ABUSE;

4-AMINOBUTYRATE TRANSAMINASE; ANIMALS; ENZYME INHIBITORS; FEMALE; GAMMA-AMINOBUTYRIC ACID; MALE; MICRODIALYSIS; PAPIO; RATS; RATS, SPRAGUE-DAWLEY; TOBACCO USE DISORDER; TOMOGRAPHY, EMISSION-COMPUTED; VIGABATRIN;

EID: 0032908565     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199901)31:1<76::AID-SYN10>3.0.CO;2-Y     Document Type: Article

References (85)

1. Altman J, Everitt Bj, Glautier S, Markou A, Nutt A, Oretti R, Phillips GD, Robbins TW. 1996. The biological, social and clinical basis of drug addiction: commentary and debate. Psychopharmacology 125: 285-345.
2. B receptor in gamma-vinyl GABA's inhibition of cocaine-induced increases in nucleus accumbens dopamine. Synapse (in press).
3. Bardo MT. 1998. Neuropharmacological mechanism of drug reward: beyond dopamine in the nucleus accumbens. Crit Rev Neurobiol 12: 37-67.
4. Bolser DC, Blythin DJ, Chapman RW, Egan RW, Hey JA, Rizzo C, Kuo S-C, Kreutner W. 1995. The pharmacology of SCH 50911: a novel, orally-active GABA-B receptor antagonist. J Pharmacol Exp Ther 274: 1393-1398.
5. B receptors as targets for drug action. Arzneim Forsch 42: 215-223.
6. Brazell MP, Mitchell SN, Joseph MH, Gray JA. 1990. Acute administration of nictoine increases the in vivo extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid and ascorbic acid preferentially in the nucleus accumbens of the rat: Comparison with caudate-putamen. Neuropharmacology 29:1177-1185.
7. Carr GD, Fibiger HC, Phillips AG. 1989. Conditioned place preference as a measure of reward. In: Liebman JM, Cooper SJ, editors. The neuropharmacological basis of reward. Oxford: Clarendon Press, p 264-319.
8. 9 Tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. Eur J Pharm 190: 259-262.
9. Chesselet M-F. 1984. Presynaptic regulation of neurotransmitter release in the brain: Facts and hypothesis. Neuroscience 12: 347-375.
10. Childress AR, McLellan AT, Ehrman RN, O'Brien CP. 1986a. Extinction of conditioned responses in abstinent cocaine or opioid users. NIDA Res Monogr 76: 189-195.
11. Childress AR, McLellan AT, Ehrman RN, O'Brien CP. 1986b. Classically conditioned responses in abstinent cocaine or opioid users. NIDA Res Monogr 76: 24-43.
12. Childress AR, McLellan AT, O'Brien CP. 1988. The role of conditioning factors in the development of drug dependence. Psychiatr. Clin North Am 9: 413-426.
13. Clarke PBS, Fibiger HC. 1987. Apparent absence of nicotine-induced conditioned place preference. Psychopharmacology 92: 84-88.
14. Clarke PBS, Fu DS, Jakubovic A, Fibiger HC. 1988. Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in animals. J Pharmacol Exp Ther 246: 701-708.
15. Corrigall WA, Coen KM. 1991. Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology 104:171-176.
16. Corrigall WA, Franklin KBJ, Coen KM, Clarke PBS. 1992. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 107: 285-289.
17. Corrigall WA, Coen KM, Adamson KL. 1994. Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res 653: 276-284.
18. Damsma G, Day J, Fibiger HC. 1989. Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. Eur J Pharmacol 168: 363-368.
19. Deneau GA, Inoki R. 1967. Nicotine self-administration in monkeys. Ann NY Acad Sci 142:277-279.
20. 11C-raclopride and positron emission tomography. J Neurosci 12: 3773-3780.
21. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13: 350-356.
22. Dewey SL, Smith GS, Logan J, Simkowitz P, Brodie JD, Volkow ND, Fowler JS, Wolf AP. 1993b. Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography PET. in normal human subjects. Proc Natl Acad Sci USA 90:11816-11820.
23. Dewey SL, Chaurasia CS, Chen C, Volkow ND, Clarkson FA Porter, SP, Straughter-Moore RM, Alexoff DL, Tedeschi D, Russo NB, Fowler JS, Brodie JD. 1997. GABAergic attenuation of cocaine-induced dopamine release and locomotor activity. Synapse 25: 393-398.
24. Dewey, SL, Morgan AE, Ashby Jr, CR Horan, B Gardner, EL Logan J, Volkow ND, Fowler JS, Kushner SA, Brodie JD. 1998. A novel strategy for the treatment of cocaine addiction. Synapse 30:119-129.
25. Di Chiara G, Imperato A. 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving animals. Proc Natl Acad Sci USA 85:5274-5278.
26. Donny EC, Caggiula AR, Knopf S, Brown C. 1995. Nicotine self-administration in animals. Psychopharmacology 122: 390-394.
27. 2 receptor ligands. J Labeled Compounds Radiopharm XXIV: 931-940.
28. Ehrman RN, Robbing SJ, Childress AR, O'Brien CP. 1992. Conditioned responses to cocaine-related stimuli in cocaine abuse patients. Psychopharmacology 107: 523-529.
29. Fiore MD. 1992. Trends in cigarette smoking in the United States: the epidemiology of tobacco use. Med Clin North Am 76: 289-303.
30. Fudala PJ, Iwamoto ET. 1986. Further studies on nicotine-induced conditioned place preference. Pharmacol Biochem Behav 25:1041-1049.
31. Fudala, PJ, Teoh KW, Iwamoto ET. 1985. Pharmacologic characterization of nicotine-induced conditioned place preference. Pharmacol Biochem Behav 22: 237-241.
32. Fuxe K, Andersson K, Harfstrand A, Agnati LF. 1988. Increases in dopamine utilization in certain limbic dopamine terminal populations after a short period of intermittent exposure of male rats to tobacco smoke. J Neural Transm 67:15-29.
33. Gardner EL. 1997. Brain reward mechanisms. In: Lowinson JH, Ruiz P, Millmna RB, Langrod JG, editors. Substance abuse: a comprehensiove textbook, 3rd ed.Baltimore: Williams and Wilkins, p 51-85.
34. Goldberg SR, Spealman RD, Goldberg DM. 1981. Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science 214: 573-575.
35. Goldstein MG. 1998. Bupropion sustained release and smoking cessation. J Clin Psychiatry 59(Suppl 4): 66-72.
36. Grant SM, Heel RC. 1991. Vigabatrin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 41: 889-926.
37. Grenhoff J, Svensson TH. 1988. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta physiol Scand 28: 351-358.
38. Grenhoff J, Aston-Jones G, Svensson TH. 1986. Selective stimulation of limbic dopamine neurons by nicotine. Acta Physiol Scand 133: 595-596.
39. Gritz ME. 1980. Smoking behavior and tobacco abuse. In: Mello NK, editor. Advances in substance abuse: behavioral and biological research. Greenwich, CT: JAI Press, p 91-158.
40. Henningfield JE. 1995. Nicotine medications for smoking cessation. New Engl J Med 333: 1196-1203.
41. Henningfield JE, Goldberg SR. 1983. Control of behavior by intravenous nicotine injections in human subjects. Pharmacol Biochem Behav 19:1021-1026.
42. Henningfield JE, Miyasato K, DR. Jasinski 1983. Cigarette smokers self-administer intravenous nicotine. Pharmacol Biochem Behav 19: 887-890.
43. Henningfield JE, London ED, Jaffe JH. 1987. nicotine reward: studies of abuse liability and physical dependence potential. In: Engel J, Oreland L, editors. Brain reward systems and abuse.New York: Raven Press, p 147-164.
44. Hoffman DC. 1989. The use of place conditioning in studying the neuropharmacology of drug reinforcement. Brain Res Bull 23: 373-387.
45. Horan P, Smith M, Gardner E, Lepore M, Ashby CR Jr. 1997. (-)-nicotine produces conditioned place preference in Lewis, but not Fischer 344 animals. Synapse 26: 93-94.
46. Hurd YL, McGregor A, Ponten M. 1997. In vivo amygdala dopamine levels modulate cocaine self-administration behaviour in the rat: D1 dopamine receptor involvement. Eur J Neurosci 12: 2541-2548.
47. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM. 1997. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 237: 1195-1202.
48. Imperato A, Mulas A, Di Chiara G. 1986. Nicotine preferentially stimulates dopamine release in the limbic system of the freely moving rat. Eur J Pharmacol 132: 337-338.
49. Jarvik ME, Henningfield JE. 1988. Pharmacological treatment of tobacco dependence. Pharmacol Biochem Behav 30: 279-294.
50. Jung MJ, Lippert B, Metcalf BW, Bohlen P, Schechter PJ. 1977. Gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem 29: 787-802.
51. B receptors in mammalian function. New York: John Wiley and Sons, p 29-45.
52. Kushner SA, Dewey SL, Kornetsky C. 1997a. Comparison of the effects of vigabatrin on cocaine self-administration and food reinforcement. Soc Neurosci Abstr 23:1942.
53. Kushner SA, Dewey SL, Kornetsky C. 1997b. The effects of gamma-vinyl GABA on cocaine-induced lowering of brain-stimulation reward thresholds. Psychopharmacology 133: 383-388.
54. Lapin EP, Maker HS, Sershen H, Hurd Y, Lajtha A. 1989. Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J Pharm Exp Ther 246: 701-708.
55. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10: 740-747.
56. Robinson TE, Berridge KC. 1993. The neural basis of drug craving; an incentive-sensitization theory of addiction. Brain Res Rev 18: 247-291.
57. Marshall DL, Redfern PH, Wonnacott S. 1995. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J Neurochem 68: 1511-1519.
58. Mereu G, Yoon KwP Boi, V Gessa, GL Naes, L Westfall, TC. 1987. Preferential stimulation of ventral tegmental dopaminergic neurons by nicotine. Eur J Pharmacol 141: 395-399.
59. Morgan AE, Dewey SL. 1998. Effects of pharmacologic increases in brain GABA levels on cocaine-induced changes in extracellular dopamine. Synapse 28: 60-65.
60. Nisell M, Nomikos GG, Svensson TH. 1994a. Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 16: 36-44.
61. Nisell M, Nomikos GG, Svensson TH. 1994b. Infusion of nicotine in the ventral tegmental area or the nucleus accumbens differentially affects accumbal dopamine release Pharmacol Toxicol 75: 348-352.
62. Nisell M, Nomikos GG, Svensson TH. 1995. Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacol Toxicol 76: 157-162.
63. O'Brien CP, Childress AR, McLellan AT, Ehrman R. 1992. A learning model of addiction. In: O'Brien CP, Jaffe JH, editors. Addictive states. New York: Raven Press, p 157-177.
64. Pollin W. 1984. The role of the addictive process as a key step in causation of all tobacco-related diseases. J Am Med Assoc 252: 20.
65. Pomerleau CS, Pomerleau OF. 1992. Euphoriant effects of nicotine in smokers. Psychopharmacology 108: 460-465.
66. Pontieri FE, Tanda G, Orzi F, Di Chiara G. 1997. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382: 255-257.
67. Porter RJ, Meldrum BS. 1998. Antiepileptic drugs. In: Katzung BG, editor. Basic and clinical pharmacology. Stamford, CT: Appelton and Lange, p 386-408.
68. Ravenholt RT. 1980. Addiction mortality in the United States, 1980: tobacco, alcohol and other substances. Pop Dev Rev 10: 697-724.
69. Roberts DC, Andrews MM. 1997. Baclofen suppression of cocaine self-administration: demonstration using a discrete trials procedure. Psychopharmacology 131: 271-277.
70. Roberts DC, Andrews MM, Vickers GJ. 1996. Baclofen attenuates the reinforcing effects of cocaine in animals. Neuropsychopharmacology 15: 417-423.
71. Mansbach RS, Rovetti CC, Freedland CS. 1998. The role of monoamine neurotransmitter systems in the nicotine discriminative stimulus. Drug and Alcohol Dependence 52: 125-1345.
72. Rocha BA, Scearce-Levie K, Lucas JJ, Hiroi N, Castanon N, Crabbe JC, Nestler EJ, Hen R. 1998. Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor. Nature Neurosci 393:175-178.
73. 3H]dopamine release by nicotine in rat nucleus accumbens. J Neurochem 49: 1449-1454.
74. Russell MAH, Stapleton JA, Feyerabend C. 1995. nicotine boost per cigarette as the controlling factor of intake regulation by smokers. In: Clarke PBS, Quik M, Adlkofer F, Thurau K, editors. Effects of nicotine on biological systems II. Berlin: Birkhauser Verlag, p 233-238.
75. Schloesser R, Simkowitz P, Bartlett EJ, Wolkin A, Smith GS, Dewey SL, Brodie JD. 1996. The study of neurotransmitter interactions using positron emission tomography and functional coupling. Clin Neuropharmacol 19: 371-389.
76. 3H]raclopride: implications for positron emission tomography of the human brain. Synapse 3: 96-97.
77. Singer G, Wallace W, Hall R. 1982. Effects of dopaminergic nucleus accumbens lesions on the acquisition of schedule induced self injection of nicotine in the rat. Pharmacol Biochem Behav 17: 579-581.
78. Sora I, Wichems SI, Takahashi C, Li XF, Zeng Z, Revay R, Lesch KP, Murphy DL, Uhl DR. 1998. cocaine reward models: conditioned place preference can be established in dopamine-and serotonin-transporter knockout mice. Proc Natl Acad Sci USA 95: 7699-7704.
79. Takada K, Yanagita T. 1997. Drug dependence study on vigabatrin in rhesus monkeys and animals. Arzneim-Forsch/Drug Res 47:1087-1095.
80. B receptors inhibits morphine-induced place preference in animals. Eur J Pharmacol 313:169-173.
81. U.S. Department of Health and Human Services. 1983. Why people smoke cigarettes. PHS Publication. Washington, DC: U.S. Government Printing Office, 83-50195.
82. U.S. Department of Health and Human Services. 1987. Smoking, Tobacco and Health. Public Health, Publication No. DHHS (CDC). Washington, DC: U.S. Government Printing Office, 87-8397.
83. Valentine, JD, Hokanson JS, Matta SG, Sharp BM. 1997. Self-administration in animals allowed unlimited access to nicotine. Psychopharmacology 133: 300-304.
84. Van Der Kooy K. 1987. In: Bozarth MA, editor. Methods of assessing the properties of abused drugs. New York: Springer-Verlag, p 229-241.
85. Wikler A. 1965. Conditioning factors in opiate addiction and relapse. In: Kassenbaum GG, Wilner DI, editors. Narcotics. New York: McGraw-Hill, p 85-100.